Loretta Nastoupil, MD

Loretta J. Nastoupil, MD is currently practicing in an underserved area in the Four Corners region at Mercy CommonSpirit in Durango, CO, since July of 2024. Dr. Nastoupil received her MD degree from UT Southwestern in Dallas, TX. Completed internship and residency at Washington University/Barnes-Jewish Hospital in St. Louis, MO. She completed fellowship at Emory University in Atlanta, GA under the mentorship of Christopher Flowers, MD. Following her training she was at MD Anderson Cancer Center in Houston, TX from 2013-2024. At the time of her departure, she was Deputy Chair of the Lymphoma/Myeloma Department and Section Chief of Indolent Lymphoma. She has experience in conducting clinical trials exploring strategies of enhancing immune therapy to eradicate B cell lymphoma. She also has experience in real world analyses exploring how novel therapies impact the treatment landscape and perform outside of a controlled environment. Her most recent venture is delivering care to an underserved area, getting back to her roots to raise her children.
Financial relationships
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:AbbvieTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:Astra ZenecaTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:BMSTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:Caribou BiosciencesTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:Daiichi SankyoTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:GenentechTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:Gilead/KiteTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:IpsenTopic:Real world AnalysesDate added:01/22/2025Date updated:01/22/2025Relationship end date:02/15/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:JanssenTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:MerckTopic:Drug Development B cell lymphomaDate added:01/22/2025Date updated:01/22/2025Relationship end date:07/01/2024

Facebook
X
LinkedIn
Forward